Stakeholder Insight: COPD - Another Reason to Quit

Introduction

COPD is a deadly disease of the elderly, with patients suffering years of progressive discomfort and disability with no pharmacological interventions able to slow the progressive decline in lung function. A large, increasing patient population demands the development of truly novel COPD-focused therapies which must be coupled with improved disease awareness and diagnosis.

Scope

Analysis of diagnosis, epidemiology, and treatment of COPD

Assessment of the extent to which physicians treat COPD severities differently

Examination of the use of drug classes and brands across the COPD sub-populations

Evaluation of future prescribing trends and the potential of novel COPD therapies

Highlights

Current treatment practice will continue to diverge from international guidelines, with the most important change being the increased use of long-acting bronchodilators in mild COPD.

The use of inhaled corticosteroids will continue to be reserved primarily for late stage disease, until alternative anti-inflammatory agents are available from 2010 onwards.

With no revolutionary new drugs in the pipeline, and novel combinations of existing classes of drugs only offering gains patient compliance, improvements in smoking cessation and pulmonary rehabilitation offer the greatest hope to COPD patients.

Reasons to Purchase

Identify the most lucrative target niche populations for developmental products

Understand how to position new COPD therapies

Gain insight into prescribing patterns and physician opinion on current treatment paradigms

December 2005

Pages: 205

Format: PDF
Table of Contents
Price: $15,200.00 / GBP7,600.00